Authors: Kenneth V I Rolston Susan E FrisbeeHume Shreyaskumar Patel Ellen F Manzullo Robert S Benjamin
Publish Date: 2009/04/22
Volume: 18, Issue: 1, Pages: 89-
Abstract
In this openlabel pilot study eligible lowrisk febrile neutropenic patients identified using predefined criteria MASCC Risk Index received oral moxifloxacin 400 mg in our emergency center and were discharged after a 4–8 h observation period to ensure clinical stability They subsequently received moxifloxacin 400 mg daily as outpatients Success of monotherapy outpatient management the development of adverse events and major medical complications were recordedThe trial was closed without reaching the target sample size of 40 patients due to slow accrual Twentyone evaluable patients were enrolled with sarcoma and breast cancer being the predominant underlying neoplasms Most patients 76 were severely neutropenic ≤100 cells/mm3 on enrollment There were 13 episodes 62 of unexplained fever and eight documented infections including five episodes 24 of bacteremia The overall success rate of monotherapy was 95 One patient with unexplained fever and persistent neutropenia required hospitalization and responded to alternative therapy No significant toxicity or severe medical complications occurred
Keywords: